pegzilarginase + cetuximab

Pegzilarginase + cetuximab is a combination therapy under investigation, most notably in oncology. **Pegzilarginase** is a recombinant, cobalt-substituted, pegylated human arginase 1 enzyme designed to reduce plasma arginine levels by catalyzing its conversion to ornithine and urea, and is primarily developed for treating arginase 1 deficiency. **Cetuximab** is a chimeric monoclonal antibody that targets the epidermal growth factor receptor (EGFR), inhibiting downstream signaling involved in tumor proliferation. There is no evidence in the literature of a clinical combination of pegzilarginase with cetuximab. Notably, combinations of EGFR inhibitors with targeted therapies (e.g., KRAS G12C inhibitors) are an active area of research in oncology, while pegzilarginase is investigated mainly for inborn errors of metabolism, not as an anti-cancer therapy in combination with cetuximab.